The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2024 | Factors that are important to consider when selecting patients with MPN for SCT
Raajit Rampal, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses factors that are important to consider when selecting patients with myeloproliferative neoplasms (MPNs) for stem cell transplantation (SCT). He emphasizes prioritizing high-risk patients and carefully determining the optimal timing for SCT. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting Fees: Incyte Corporation, Celgene/BMS, Blueprint, Abbvie, CTI, Stemline, Galecto, Pharmaessentia, Jubilant, Constellation/Morphosys, Sierra Oncology/GSK, Protagonist, Cogent, Sumitomo Dainippon, Kartos, Servier, Zentalis, Karyopharm; Research Funding: Constellation pharmaceuticals, Ryvu, Zentalis, Stemline Therapeutics, Incyte Corporation.
